

Supplementary Appendix

Manuscript: Hydroxychloroquine for prevention of COVID-19 mortality: a population-based cohort study

Open source materials: All code for data management and analyses and raw outputs are openly shared online for review and re-use (<https://github.com/opensafely/hydroxychloroquine-research>). All iterations of the pre-specified study protocol are archived with version control (<https://github.com/opensafely/hydroxychloroquine-research/tree/master/protocol>).

Table of Contents

Information governance and ethics	2
Patient and public involvement	2
eFigure 1. Study diagram	3
eFigure 2. Directed acyclic graph	4
eTable 1. Demographic and clinical characteristics of 167,874 patients with rheumatoid arthritis	5
eTable 2. Demographic and clinical characteristics of 26,763 patients with systemic lupus erythematosus (SLE)	7
eTable 3. Interactions with HCQ use on the risk of COVID-19 mortality	9
eTable 4. Sensitivity analyses of the association between HCQ use and the risk of COVID-19 mortality	11
eTable 5. Bias-adjusted associations using a range of estimated prevalence of biologic DMARDs and associations with COVID-19 mortality	12
eTable 6. Comparison of estimates between stratified Cox proportional hazards models and Royston-Parmar flexible parametric models	13
Estimating prevalence of biologic DMARDs by exposure group for eTable 5	14
References	15


Information governance and ethics

NHS England is the data controller; TPP is the data processor; and the key researchers on OpenSAFELY are acting on behalf of NHS England. OpenSAFELY is hosted within the TPP environment which is accredited to the ISO 27001 information security standard and is NHS IG Toolkit compliant;^{1,2} patient data are pseudonymised for analysis and linkage using industry standard cryptographic hashing techniques; all pseudonymised datasets transmitted for linkage onto OpenSAFELY are encrypted; access to the platform is via a virtual private network (VPN) connection, restricted to a small group of researchers who hold contracts with NHS England and only access the platform to initiate database queries and statistical models. All database activity is logged; only aggregate statistical outputs leave the platform environment following best practice for anonymisation of results such as statistical disclosure control for low cell counts.³ The OpenSAFELY platform adheres to the data protection principles of the UK Data Protection Act 2018 and the EU General Data Protection Regulation (GDPR) 2016. In March 2020, the Secretary of State for Health and Social Care used powers under the UK Health Service (Control of Patient Information) Regulations 2002 (COPI) to require organisations to process confidential patient information for the purposes of protecting public health, providing healthcare services to the public and monitoring and managing the COVID-19 outbreak and incidents of exposure.⁴ Taken together, these provide the legal bases to link patient datasets on the OpenSAFELY platform. This study was approved by the Health Research Authority (REC reference 20/LO/0651) and by the LSHTM Ethics Board (ref 21863).

Patient and public involvement


Patients were not formally involved in developing this specific study design that was developed rapidly in the context of a global health emergency. We have developed a publicly available website <https://opensafely.org/> through which we invite any patient or member of the public to contact us regarding this study or the broader OpenSAFELY project.

eFigure 1. Study diagram



Abbreviations: STP, Sustainability and Transformation Partnership (a National Health Service administrative region); sDMARD, synthetic disease-modifying antirheumatic drug; IMD, index of multiple deprivation; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; COVID-19, coronavirus disease 2019;
Notes: End of follow-up was earliest of: date of death, seven days prior to last date of Office of National Statistics mortality data to account for reporting lag, or date of first hydroxychloroquine prescription on or after index date (for patients without hydroxychloroquine use at index date)

eFigure 2. Directed acyclic graph



Minimal adjustment set: age, sex, ethnicity, geographic region, other immunosuppressives

Notes: Disease severity referred to that of rheumatoid arthritis or systemic lupus erythematosus. Other immunosuppressives included other synthetic and biologic disease-modifying antirheumatic drugs and oral corticosteroids. Other comorbidities included hypertension, diabetes severity, heart disease, liver disease, respiratory disease excluding asthma, kidney disease, stroke, dementia, cancer

eTable 1. Demographic and clinical characteristics of 167,874 patients with rheumatoid arthritis

	Total	No HCQ	HCQ
Sample size, n	167,874 (100.0)	144,151 (100.0)	23,723 (100.0)
Demographics			
Age, years			
Median (IQR)	67 (56-76)	67 (56-76)	65 (55-73)
18-39	10,088 (6.0)	8,957 (6.2)	1,131 (4.8)
40-49	15,111 (9.0)	12,822 (8.9)	2,289 (9.6)
50-59	30,917 (18.4)	26,023 (18.1)	4,894 (20.6)
60-69	40,035 (23.8)	33,464 (23.2)	6,571 (27.7)
70-79	44,491 (26.5)	38,279 (26.6)	6,212 (26.2)
≥80	27,232 (16.2)	24,606 (17.1)	2,626 (11.1)
Sex			
Female	116,406 (69.3)	99,238 (68.8)	17,168 (72.4)
Male	51,468 (30.7)	44,913 (31.2)	6,555 (27.6)
Ethnicity			
White	115,869 (69.0)	99,746 (69.2)	16,123 (68.0)
South Asian	8,511 (5.1)	7,081 (4.9)	1,430 (6.0)
Black	1,981 (1.2)	1,688 (1.2)	293 (1.2)
Mixed	881 (0.5)	724 (0.5)	157 (0.7)
Other	1,354 (0.8)	1,168 (0.8)	186 (0.8)
Missing	39,278 (23.4)	33,744 (23.4)	5,534 (23.3)
Index of multiple deprivation			
1 (least deprived)	33,439 (19.9)	28,787 (20.0)	4,652 (19.6)
2	33,922 (20.2)	29,199 (20.3)	4,723 (19.9)
3	33,702 (20.1)	28,860 (20.0)	4,842 (20.4)
4	33,311 (19.8)	28,614 (19.9)	4,697 (19.8)
5 (most deprived)	33,500 (20.0)	28,691 (19.9)	4,809 (20.3)
Residence type			
Rural	39,577 (23.6)	33,829 (23.5)	5,748 (24.2)
Urban	128,297 (76.4)	110,322 (76.5)	17,975 (75.8)
Body mass index, kg/m ²			
<18.5	3,721 (2.2)	3,205 (2.2)	516 (2.2)
18.5-24.9	48,185 (28.7)	41,443 (28.7)	6,742 (28.4)
25-29.9	54,164 (32.3)	46,823 (32.5)	7,341 (30.9)
30-34.9	31,102 (18.5)	26,617 (18.5)	4,485 (18.9)
35-39.9	13,159 (7.8)	11,103 (7.7)	2,056 (8.7)
≥40	6,778 (4.0)	5,521 (3.8)	1,257 (5.3)
Missing	10,765 (6.4)	9,439 (6.5)	1,326 (5.6)
Smoking status			

Never	63,068 (37.6)	54,640 (37.9)	8,428 (35.5)
Former	81,304 (48.4)	69,376 (48.1)	11,928 (50.3)
Current	23,023 (13.7)	19,696 (13.7)	3,327 (14.0)
Missing	479 (0.3)	439 (0.3)	40 (0.2)
Clinical conditions			
Diabetes			
No diabetes	136,690 (81.4)	116,885 (81.1)	19,805 (83.5)
Diabetes, HbA1c <7.5%	20,294 (12.1)	17,659 (12.3)	2,635 (11.1)
Diabetes, HbA1c ≥7.5%	8,171 (4.9)	7,261 (5.0)	910 (3.8)
Diabetes, missing HbA1c	2,719 (1.6)	2,346 (1.6)	373 (1.6)
eGFR, ml/min/1.73m ²			
≥60	117,522 (70.0)	98,630 (68.4)	18,892 (79.6)
30-59	21,998 (13.1)	19,189 (13.3)	2,809 (11.8)
<30	1,622 (1.0)	1,445 (1.0)	177 (0.7)
Missing	26,732 (15.9)	24,887 (17.3)	1,845 (7.8)
Heart disease	27,249 (16.2)	23,708 (16.4)	3,541 (14.9)
Liver disease	2,111 (1.3)	1,787 (1.2)	324 (1.4)
Respiratory disease (excluding asthma)	23,925 (14.3)	20,083 (13.9)	3,842 (16.2)
Neurological condition	10,896 (6.5)	9,646 (6.7)	1,250 (5.3)
Hypertension	73,863 (44.0)	63,955 (44.4)	9,908 (41.8)
Cancer	17,603 (10.5)	15,238 (10.6)	2,365 (10.0)
Immunosuppression	2,200 (1.3)	1,851 (1.3)	349 (1.5)
Influenza vaccination 2019/20	108,883 (64.9)	91,697 (63.6)	17,186 (72.4)
Other medications			
Other sDMARD	68,490 (40.8)	54,401 (37.7)	14,089 (59.4)
Azithromycin	850 (0.5)	691 (0.5)	159 (0.7)
Oral corticosteroid	28,858 (17.2)	23,968 (16.6)	4,890 (20.6)
NSAID	30,606 (18.2)	25,042 (17.4)	5,564 (23.5)

Abbreviations: IQR, interquartile range; HbA1c, glycated haemoglobin; eGFR, estimated glomerular filtration rate; sDMARD, synthetic disease-modifying antirheumatic drug; NSAID, non-steroidal anti-inflammatory drug

eTable 2. Demographic and clinical characteristics of 26,763 patients with systemic lupus erythematosus (SLE)

	Total	No HCQ	HCQ
Sample size, n	26,763 (100.0)	19,917 (100.0)	6,846 (100.0)
Demographics			
Age, years			
Median (IQR)	58 (47-70)	60 (48-71)	55 (44-66)
18-39	3,621 (13.5)	2,476 (12.4)	1,145 (16.7)
40-49	4,327 (16.2)	3,007 (15.1)	1,320 (19.3)
50-59	6,169 (23.1)	4,434 (22.3)	1,735 (25.3)
60-69	5,664 (21.2)	4,262 (21.4)	1,402 (20.5)
70-79	4,747 (17.7)	3,811 (19.1)	936 (13.7)
≥80	2,235 (8.4)	1,927 (9.7)	308 (4.5)
Sex			
Female	22,034 (82.3)	15,868 (79.7)	6,166 (90.1)
Male	4,729 (17.7)	4,049 (20.3)	680 (9.9)
Ethnicity			
White	16,828 (62.9)	12,621 (63.4)	4,207 (61.5)
South Asian	1,987 (7.4)	1,421 (7.1)	566 (8.3)
Black	1,016 (3.8)	737 (3.7)	279 (4.1)
Mixed	398 (1.5)	281 (1.4)	117 (1.7)
Other	484 (1.8)	340 (1.7)	144 (2.1)
Missing	6,050 (22.6)	4,517 (22.7)	1,533 (22.4)
Index of multiple deprivation			
1 (least deprived)	5,529 (20.7)	4,167 (20.9)	1,362 (19.9)
2	5,515 (20.6)	4,152 (20.8)	1,363 (19.9)
3	5,240 (19.6)	3,940 (19.8)	1,300 (19.0)
4	5,166 (19.3)	3,788 (19.0)	1,378 (20.1)
5 (most deprived)	5,313 (19.9)	3,870 (19.4)	1,443 (21.1)
Residence type			
Rural	6,079 (22.7)	4,476 (22.5)	1,603 (23.4)
Urban	20,684 (77.3)	15,441 (77.5)	5,243 (76.6)
Body mass index, kg/m ²			
<18.5	651 (2.4)	487 (2.4)	164 (2.4)
18.5-24.9	8,796 (32.9)	6,608 (33.2)	2,188 (32.0)
25-29.9	7,706 (28.8)	5,844 (29.3)	1,862 (27.2)
30-34.9	4,213 (15.7)	3,035 (15.2)	1,178 (17.2)
35-39.9	1,840 (6.9)	1,269 (6.4)	571 (8.3)
≥40	949 (3.5)	635 (3.2)	314 (4.6)
Missing	2,608 (9.7)	2,039 (10.2)	569 (8.3)
Smoking status			

Never	11,116 (41.5)	8,065 (40.5)	3,051 (44.6)
Former	11,128 (41.6)	8,364 (42.0)	2,764 (40.4)
Current	4,388 (16.4)	3,383 (17.0)	1,005 (14.7)
Missing	131 (0.5)	105 (0.5)	26 (0.4)
Clinical conditions			
Diabetes			
No diabetes	23,140 (86.5)	17,069 (85.7)	6,071 (88.7)
Diabetes, HbA1c <7.5%	2,419 (9.0)	1,901 (9.5)	518 (7.6)
Diabetes, HbA1c ≥7.5%	827 (3.1)	669 (3.4)	158 (2.3)
Diabetes, missing HbA1c	377 (1.4)	278 (1.4)	99 (1.4)
eGFR, ml/min/1.73m ²			
≥60	15,849 (59.2)	10,976 (55.1)	4,873 (71.2)
30-59	2,530 (9.5)	1,964 (9.9)	566 (8.3)
<30	322 (1.2)	253 (1.3)	69 (1.0)
Missing	8,062 (30.1)	6,724 (33.8)	1,338 (19.5)
Heart disease	3,360 (12.6)	2,584 (13.0)	776 (11.3)
Liver disease	607 (2.3)	440 (2.2)	167 (2.4)
Respiratory disease (excluding asthma)	2,755 (10.3)	2,076 (10.4)	679 (9.9)
Neurological condition	1,822 (6.8)	1,357 (6.8)	465 (6.8)
Hypertension	9,541 (35.6)	7,162 (36.0)	2,379 (34.8)
Cancer	2,425 (9.1)	1,906 (9.6)	519 (7.6)
Immunosuppression	769 (2.9)	548 (2.8)	221 (3.2)
Influenza vaccination 2019/20	13,412 (50.1)	9,415 (47.3)	3,997 (58.4)
Other medications			
Other sDMARD	3,033 (11.3)	1,379 (6.9)	1,654 (24.2)
Azithromycin	98 (0.4)	60 (0.3)	38 (0.6)
Oral corticosteroid	4,819 (18.0)	2,824 (14.2)	1,995 (29.1)
NSAID	2,750 (10.3)	1,644 (8.3)	1,106 (16.2)

Abbreviations: IQR, interquartile range; HbA1c, glycated haemoglobin; eGFR, estimated glomerular filtration rate; sDMARD, synthetic disease-modifying antirheumatic drug; NSAID, non-steroidal anti-inflammatory drug

eTable 3. Interactions with HCQ use on the risk of COVID-19 mortality

	No. events	DAG-Informed Adjustment		
		HR	95% CI	p-value
Age				
18-59 years				
No HCQ	18 (0.0)	1	(ref)	0.78
HCQ	6 (0.0)	1.50	(0.59-3.79)	
60-69 years				
No HCQ	40 (0.1)	1	(ref)	
HCQ	10 (0.1)	1.17	(0.58-2.35)	
70-79 years				
No HCQ	148 (0.4)	1	(ref)	
HCQ	25 (0.3)	0.97	(0.63-1.48)	
≥80 years				
No HCQ	271 (1.0)	1	(ref)	
HCQ	29 (1.0)	0.92	(0.62-1.35)	
Other sDMARD				
No				
No HCQ	311 (0.3)	1	(ref)	0.22
HCQ	41 (0.3)	1.14	(0.82-1.59)	
Yes				
No HCQ	166 (0.3)	1	(ref)	
HCQ	29 (0.2)	0.83	(0.56-1.24)	
Oral corticosteroid				
No				
No HCQ	296 (0.2)	1	(ref)	0.97
HCQ	38 (0.2)	1.00	(0.71-1.41)	
Yes				
No HCQ	181 (0.7)	1	(ref)	
HCQ	32 (0.5)	0.99	(0.68-1.45)	
NSAID				
No				
No HCQ	443 (0.3)	1	(ref)	0.11
HCQ	62 (0.3)	0.98	(0.75-1.29)	
Yes				
No HCQ	34 (0.1)	1	(ref)	
HCQ	8 (0.1)	1.18	(0.55-2.56)	

Abbreviations: HCQ, hydroxychloroquine; COVID-19, coronavirus disease 2019; DAG, directed acyclic graph; CI, confidence interval; sDMARD, synthetic disease-modifying antirheumatic drug; STP, Sustainability and Transformation Partnership (a National Health Service administrative region)

Notes: DAG-Informed models adjusted for age, sex, ethnicity, other immunosuppressives (other sDMARDs, oral corticosteroids) and stratified by population (i.e., RA or SLE) and STP of the patient's general practice to allow for geographical differences in baseline hazards.

eTable 4. Sensitivity analyses of the association between HCQ use and the risk of COVID-19 mortality

	No. events	DAG-Informed Adjustment	
		HR	95% CI
Ethnicity adjustments			
All patients, without adjustment for ethnicity			
No HCQ	477 (0.3)	1	(ref)
HCQ	70 (0.2)	1.03	(0.80-1.33)
Exclude individuals with missing ethnicity			
No HCQ	358 (0.3)	1	(ref)
HCQ	48 (0.2)	0.94	(0.69-1.28)
Additional adjustment for ethnicity			
No HCQ	358 (0.3)	1	(ref)
HCQ	48 (0.2)	0.94	(0.69-1.27)
Shorten exposure ascertainment to 3 months			
No HCQ	477 (0.3)	1	(ref)
HCQ	70 (0.2)	1.03	(0.80-1.33)
Population adjustment			
Change from stratifying to indicator variable			
No HCQ	477 (0.3)	1	(ref)
HCQ	70 (0.2)	0.94	(0.69-1.27)
Model populations separately			
Rheumatoid arthritis (RA)			
No HCQ	449 (0.3)	1	(ref)
HCQ	60 (0.3)	0.98	(0.75-1.29)
Systemic lupus erythematosus (SLE)			
No HCQ	28 (0.1)	1	(ref)
HCQ	10 (0.1)	1.64	(0.68-3.97)

Abbreviations: HCQ, hydroxychloroquine; COVID-19, coronavirus disease 2019; DAG, directed acyclic graph; CI, confidence interval; sDMARD, synthetic disease-modifying antirheumatic drug; STP, Sustainability and Transformation Partnership (a National Health Service administrative region)

Notes: DAG-Informed models adjusted for age, sex, ethnicity, other immunosuppressives (other sDMARDs, oral corticosteroids) and stratified by population (i.e., RA or SLE) and STP of the patient's general practice to allow for geographical differences in baseline hazards.

eTable 5. Bias-adjusted associations using a range of estimated prevalence of biologic DMARDs and associations with COVID-19 mortality

Prevalence of bDMARD among exposed	Prevalence of bDMARD among unexposed	Association between bDMARD and COVID-19 mortality			
		HR 0.80	HR 0.90	HR 1.10	HR 1.20
18%	21%	1.02 (0.79-1.32)	1.03 (0.79-1.32)	1.03 (0.80-1.33)	1.03 (0.80-1.34)
3%	30%	0.97 (0.75-1.26)	1.00 (0.78-1.29)	1.06 (0.82-1.36)	1.08 (0.84-1.40)
30%	3%	1.09 (0.84-1.40)	1.06 (0.82-1.36)	1.00 (0.78-1.29)	0.98 (0.76-1.26)

Abbreviations: bDMARD, biologic disease-modifying antirheumatic drug; COVID-19, coronavirus disease 2019; HR, hazard ratio

eTable 6. Comparison of estimates between stratified Cox proportional hazards models and Royston-Parmar flexible parametric models

	Stratified Cox (stcox)		Flexible parametric (stpm2)	
	HR	95% CI	HR	95% CI
COVID-19 mortality				
HCQ, yes vs. no	1.03	(0.80-1.33)	1.03	(0.80-1.33)
Sex, male vs. female	1.46	(1.23-1.74)	1.45	(1.22-1.72)
Age, spline 1	1.05	(0.98-1.13)	1.05	(0.98-1.13)
Age, spline 2	1.08	(0.97-1.19)	1.08	(0.97-1.19)
Age, spline 3	0.75	(0.50-1.11)	0.74	(0.50-1.10)
Other sDMARD, yes vs. no	0.93	(0.78-1.12)	0.91	(0.76-1.09)
Oral corticosteroid, yes vs. no	2.47	(2.07-2.93)	2.45	(2.06-2.91)
Non COVID-19 mortality				
HCQ, yes vs. no	1.00	(0.87-1.15)	1.00	(0.87-1.15)
Sex, male vs. female	1.25	(1.14-1.37)	1.25	(1.14-1.37)
Age, spline 1	1.06	(1.03-1.10)	1.06	(1.03-1.10)
Age, spline 2	1.03	(0.98-1.09)	1.03	(0.98-1.09)
Age, spline 3	0.94	(0.77-1.14)	0.94	(0.77-1.14)
Other sDMARD, yes vs. no	0.68	(0.61-0.75)	0.68	(0.62-0.75)
Oral corticosteroid, yes vs. no	2.03	(1.85-2.23)	2.03	(1.85-2.22)

Note: Cox models (Stata command: stcox) were stratified on STP and RA/SLE population. Royston-Parmar flexible parametric models (Stata command: stpm2) were stratified on STP and included a binary indicator for RA/SLE population as a fixed effect.

Estimating prevalence of biologic DMARDs by exposure group for eTable 5

We applied Bayes' rule to obtain estimates of the prevalence of biologic DMARDs by exposure group.

Bayes' rule definition:

$$P(A|B) = \frac{P(B|A) P(A)}{P(B)}$$

In 2017, among 400,000 rheumatoid arthritis patients in the UK, 84,200 (21%) were treated with biologics.⁵ Previous drug utilisation research has shown that 12% of rheumatoid arthritis patients on biologics were co-prescribed hydroxychloroquine.⁶ In our cohort of 167,874 patients with rheumatoid arthritis, 23,723 (14%) were prescribed hydroxychloroquine.

We substituted biologics for A and hydroxychloroquine use for B in Bayes' rule.

Bayes' rule application:

$$P(B|HCQ) = \frac{P(HCQ|B) P(B)}{P(HCQ)}$$

$$P(B|HCQ) = \frac{0.12 \times 0.21}{0.14} = 0.18$$

By law of total probability:

$$P(B) = P(B|HCQ) P(HCQ) + P(B|\underline{HCQ}) P(\underline{HCQ})$$

$$0.21 = 0.18 \times 0.14 + P(B|\underline{HCQ}) \times 0.86$$

$$P(B|\underline{HCQ}) = \frac{0.21 - (0.18 \times 0.14)}{0.86} = 0.21$$

Given the above assumptions, we estimated prevalence of biologic DMARDs to be 18% among hydroxychloroquine users and 21% among those not prescribed hydroxychloroquine.

We used these estimates to calculate bias-adjusted associations in quantitative bias analyses. To account for uncertainty in these estimates and any variation in prescribing practices between rheumatoid arthritis and systemic lupus erythematosus patient populations, we also examined more extreme values of prevalence (range 3-30%).

References

1. NHS Digital. Data Security and Protection Toolkit. 2020. Accessed August 11, 2020. <https://digital.nhs.uk/data-and-information/looking-after-information/data-security-and-information-governance/data-security-and-protection-toolkit>
2. NHS Digital. BETA - Data Security Standards. 2020. Accessed August 11, 2020. <https://digital.nhs.uk/about-nhs-digital/our-work/nhs-digital-data-and-technology-standards/framework/beta---data-security-standards>
3. NHS Digital. ISB1523: Anonymisation Standard for Publishing Health and Social Care Data. 2020. Accessed August 11, 2020. <https://digital.nhs.uk/data-and-information/information-standards/information-standards-and-data-collections-including-extractions/publications-and-notifications/standards-and-collections/isb1523-anonymisation-standard-for-publishing-health-and-social-care-data>
4. Secretary of State for Health-UK Government. Coronavirus (COVID-19): notification to organisations to share information. 2020. Accessed August 11, 2020. <https://www.gov.uk/government/publications/coronavirus-covid-19-notification-of-data-controllers-to-share-information>
5. Kim H. The Roles of Biosimilars in Patient Access to Biologics in UK. Accessed August 11, 2020. <https://www.england.nhs.uk/expo/wp-content/uploads/sites/18/2018/09/12.30-Improving-patient-care-with-biologics-in-the-management-of-RA-Celltrion-Healthcare-P2C.pdf>
6. Choy E, Taylor P, McAuliffe S, Roberts K, Sargeant I. Variation in the use of biologics in the management of rheumatoid arthritis across the UK. *Curr Med Res Opin.* 2012;28(10):1733-1741.